AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01351298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% xylometazoline hydrochloride
Description: Decongestant
Study NCT01351298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic normal saline
Description: Placebo
Study NCT02529826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular Biopsy
Description: An open testicular biopsy will be performed by an attending urologist under general anesthesia.
Study NCT00140504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medcheck message
Description: Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
Study NCT00004070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Study NCT00608205 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
Study NCT00608205 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
Study NCT04527471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ensifentrine Dose 1
Description: Study drug delivered twice daily via pMDI
Study NCT04527471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pMDI
Description: Placebo delivered twice daily via pMDI
Study NCT03378622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anchor
Description: Anchor technique for mesh attachment
Study NCT03378622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Suture technique for mesh attachment
Study NCT00287287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
Study NCT04872426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, insulin infusion
Description: Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
Study NCT01680185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Description: all covered above
Study NCT01680185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin isophane, Humulin N (Eli Lilly)
Description: all covered above
Study NCT01680185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: all covered above
Study NCT05582733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Description: hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
Study NCT05582733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traction
Description: Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
Study NCT02721797 — intervention group
Intervention type: PROCEDURE
Intervention: Orthopaedic & Gynaecology surgery
Description: Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
Study NCT02342444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium Injection 30 mg BID
Study NCT02342444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium Injection 40 mg QD
Study NCT03840746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato, onion and lovage soup (TOL)
Description: Soup
Study NCT03840746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOL soup with inulin
Description: Soup
Study NCT02303561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP
Description: Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
Study NCT02303561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
Study NCT05433428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lubricant Eye Drops
Description: Prolonged use of lubricant eye drops pre and post-op.
Study NCT05433428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Preservative Free
Description: Preservative free eye drops
Study NCT05433428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative
Description: Eyedrops with preservatives
Study NCT05433428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Preservative
Description: Eyedrops with preservatives
Study NCT02916979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 daily for 5 days
Study NCT02916979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan: 100 mg/m2 daily for 4 days
Study NCT02916979 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rabbit ATG
Description: Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4
Study NCT02916979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11
Study NCT03942510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise with blood flow restriction
Description: High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
Study NCT03775356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of hypotension and/or reduction of anesthetics
Description: The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
Study NCT01830920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-184
Description: THR-184 is a synthetic oligopeptide administered intravenously.
Study NCT01830920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A normal saline solution identical in appearance to the active drug solution
Study NCT02655627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based exercise training
Study NCT02655627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group exercise training
Study NCT02655627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity counselling via a brochure
Study NCT04449042 — intervention group
Intervention type: PROCEDURE
Intervention: airway management during sedation or general anesthesia
Description: airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
Study NCT04388059 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
Study NCT02985151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syneron-Candela CO2RE Laser
Description: This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
Study NCT02985151 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Syneron-Candela CO2RE Laser
Description: This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
Study NCT03075033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shikani optical stylet
Description: Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
Study NCT03075033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic bronchoscope for
Description: AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
Study NCT00636831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic: cefazolin Sodium
Description: 1g continuous IV at 30 minutes before starting operation
Study NCT00636831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic: cefazolin Sodium
Description: 1g continuous IV at 30 minutes before starting operation
Study NCT01460251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
Study NCT01081561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
Study NCT00532597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Study NCT00532597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low flux hemodialysis
Study NCT00231868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Pelvic Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
Study NCT00231868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Pelvic Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
Study NCT00231868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
Study NCT01123785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-8875
Description: eye drops for 14 days in one eye
Study NCT01123785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched vehicle-control
Study NCT01730677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib 1000mg, once daily
Study NCT01730677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
Study NCT01806233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
Study NCT01806233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
Study NCT01208558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day.
Study NCT01208558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
Study NCT01208558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
Study NCT02239393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).
Study NCT03640351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1. Use of preservative free diquafosol ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
Study NCT03640351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
Study NCT03640351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
Study NCT02133183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01498523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: 600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
Study NCT01498523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: camel milk powder solution
Description: 72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
Study NCT01498523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raw cow milk
Description: 50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
Study NCT01498523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: 25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
Study NCT02921529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints
Study NCT02921529 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: false stimulation
Description: Electrodes were attached to specific acupoints without electric current
Study NCT03965247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study NCT03965247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Rayotabs
Study NCT03824353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Intelligence Training
Description: The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
Study NCT03824353 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Healthy Living Program
Description: A placebo condition delivered online which presents health-related information only.
Study NCT00603902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg once daily (QD)
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Study NCT01002872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate (Fosrenol)
Description: Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner